BioMedNewsBreaks

WednesdayDec 23, 2020 9:00 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Pricing of $10M Public Offering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock and warrants to purchase up to 2,500,000 shares of common stock. According to the update, the shares of common stock and warrants are being sold together at a combined public offering price of $2.00 per share and warrant. The warrants will have an exercise price of $2.20 per share and will be immediately exercisable and expire five years from…

Continue Reading

TuesdayDec 22, 2020 2:55 pm

BioMedNewsBreaks – Why RYAH Group Inc. Is ‘One to Watch’

RYAH Group is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through its IoT dose-measuring devices and AI analytics, RYAH is focused on expanding understanding of the value of devices combined with data to positively impact the future treatment of patients for various medical conditions. A recent article discussing the company reads, “Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed…

Continue Reading

TuesdayDec 22, 2020 2:41 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Takes Game-Changing Visualization Method to the Next Level

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is at the forefront of change in its focus to establish a new standard of care in visualizing cancer. Minimally invasive surgery (“MIS”) using white light to illuminate tumor growth is the current standard of care for bladder cancer. This method is highly effective for visualizing cancerous tumors that protrude above the bladder’s wall. However, due to the difficulty in distinguishing flat tumors from normal tissue, it is nearly impossible to visualize the margins of the tumor under current standards. Game-changing to the industry has been the introduction of blue…

Continue Reading

TuesdayDec 22, 2020 2:28 pm

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Aims to Identify Best Delivery Method for Lead Drug Candidate

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, recently submitted a protocol amendment request to the U.S. Food and Drug Administration (“FDA”). Approval of the amendment will allow AzurRx to modify its current Phase 2b OPTION 2 trial of MS1819 in cystic fibrosis (“CF”) patients to add a study arm that uses immediate release capsules (https://ibn.fm/SxH8F). The existing study arm uses delayed release capsules, so the expansion will allow AzurRx to compare data from both arms to determine the best delivery method for its lead product, an exocrine pancreatic…

Continue Reading

TuesdayDec 22, 2020 1:21 pm

BioMedNewsBreaks – TPT Global Tech Inc. (TPTW) Announces Launch of ‘QuikLAB’ and ‘QuikPASS’ Apps

TPT Global Tech (OTC: TPTW), a provider of telecommunications, medical technology, media content for domestic and international syndication as well as technology solutions, today announced the release of two new products and services for use at its TPT Med Tech division. These include its "QuikLAB" App, designed for use in monitoring patient testing and vaccination history, and its "QuikPASS" Mobile App. QuikPASS is designed to allow entrance to any facility or country based on patient test and vaccination results on a real-time basis worldwide. The QuikPASS App will be offered free of charge to U.S. and international consumer markets. TPT…

Continue Reading

TuesdayDec 22, 2020 12:28 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Reaches Another Significant Milestone with Scaled-up Production of Clinical-Grade REQORSA(TM)

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced its completion of the manufacturing scale-up of REQORSA(TM) immunogene therapy. Subject to satisfactory completion of final testing currently underway, the clinical-grade production is intended to supply Genprex’s upcoming Acclaim-1 and Acclaim-2 clinical trials for the treatment of non-small cell lung cancer. The company recently announced the successful manufacturing technology transfer to commercial contract development and manufacturing organizations (“CDMOs”) as well as the successful engineering run of REQORSA, which passed all testing specifications. “The scaled-up production of clinical-grade REQORSA is yet another significant manufacturing milestone…

Continue Reading

TuesdayDec 22, 2020 11:13 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) CEO Talks Benefits of Disposable Brain Diagnostic Tools

Brain Scientific (OTCQB: BRSF) co-founder and CEO Boris Goldstein penned a recent article for “Healthcare” magazine. Titled “Brain Scientific: Neurology’s need for disposable solutions,” the article provides an overview of the need for new devices in the neurology market and the advantages of disposable brain diagnostic tools. Goldstein noted that his interest in brain diagnostic tools began when he was studying at college, where he used clustering analysis for Rorschach testing. As the founder of BrainRX, he was involved in pre-Alzheimer diagnostic and software development, and he was always searching for places to obtain data for artificial analysis or data correlation.…

Continue Reading

TuesdayDec 22, 2020 10:30 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Finalizes Agreement to Provide RPM Solution to Presbyterian Medical Services

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has inked an agreement with one of the largest integrated healthcare systems in the state of New Mexico to provide remote patient monitoring (“RPM”). The partnership with Presbyterian Medical Services begins Jan. 1, 2021. The agreement, which followed a rigorous request for proposal (“RFP”) process, reflects DRIO’s shift in focus to B2B2C and outlines the company’s commitment to provide access to Dario's next-generation, AI-powered digital therapeutics tools and quality care to patients living with chronic conditions, such as diabetes and hypertension. "We are very pleased to partner with Presbyterian Medical Services in…

Continue Reading

FridayDec 18, 2020 2:24 pm

BioMedNewsBreaks – Why Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Is ‘One to Watch’

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company that is focused on establishing a new standard of care in visualizing cancer. The company’s initial focus is on bladder cancer and its first product is the i/Blue Imaging(TM) System. Based on advanced optics, light sensors and employing patented ultrasensitive imaging technology, Imagin believes its system can significantly improve surgeons’ ability to visualize and remove cancer cells. A recent article discussing the company reads, “Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with…

Continue Reading

FridayDec 18, 2020 1:33 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Marks Significant Milestone with Commencement of CSE Trading

Tryp Therapeutics (CSE: TRYP) today announced that its common shares have commenced trading on the Canadian Securities Exchange ("CSE") under the symbol "TRYP" effective Dec. 18, 2020. "Trading on the CSE is a significant milestone in Tryp's mission to transform the treatment of neuropsychiatric diseases with safe and effective psychedelic medicines," said Tryp CEO James Kuo, MD. "All of the drugs within our portfolio have well characterized safety profiles including our drug candidate for soft tissue sarcoma, which has been in multiple phase 2 clinical trials. We are looking forward to utilizing the experience and dedication of our management team…

Continue Reading